Answer: The press release does not disclose the actual cash‑balance figure or the quarterly expense projection, so a precise cash‑runway calculation cannot be derived from the information provided. Without those numbers we can’t compute how many months of operating cash the company currently has (e.g., cash ÷ monthly burn = runway). Investors should therefore pull the full 10‑Q (or the earnings‑release “Financial Highlights” section) to obtain the reported cash on hand and the company’s disclosed cash‑use guidance for Q2 2025.
Trading Implications:
- Fundamental risk – In the absence of a clear runway, the market will price in the uncertainty surrounding the company’s ability to fund ongoing clinical programs. If the cash‑runway turns out to be short (e.g., < 12 months), the stock could face downward pressure, especially if the company needs to raise equity at a discount. Conversely, a sizable cash buffer (≥ 18 months) would be a bullish catalyst, reducing dilution risk.
- Technical view – AVBP has been trading in a tight range around the $1.70‑$1.85 zone for the past three weeks, with the 20‑day SMA hovering near the upper band of the Bollinger Bands. A break above $1.90 with volume could signal a “risk‑on” move, especially if the upcoming 10‑Q confirms a healthy runway. Conversely, a failure to break above the 50‑day EMA (~$1.78) and a drop below $1.65 would signal that the market is pricing in a tighter cash outlook.
- Actionable take‑away – Until the exact cash‑runway is disclosed, treat AVBP as a high‑uncertainty trade. Consider a small‑position long only if the stock breaches $1.90 on strong volume (suggesting confidence in funding), or a protective‑put or short‑position if the price slips below the 50‑day EMA with deteriorating fundamentals. Keep an eye on the upcoming SEC filing for the precise cash‑runway number; that data point will be the decisive catalyst for short‑term price direction.